药物研究评论：2023 年

全球滥用药物 (DOA) 检测市场规模预计将从 2022 年的 52 亿美元增至 2027 年的 81 亿美元，预测期内的复合年增长率为 9.3%。

全球生物工程蛋白质药物市场规模预计将从 2022 年的 3,541 亿美元增至 2027 年的 5,213 亿美元，预测期内的复合年增长率为 8.0%。

全球疼痛管理药物和设备市场规模预计将从 2023 年的 年终的 1,099 亿美元，预测期内的复合年增长率为 5.4%。

医药市场是世界上最大的产业之一，并且不断成长。在製药业，研究和开发始终在进行中，包括推出新药和改善现有药物的性能。然而，新药从研发到上市大概需要12到13年的时间，而现有药物的价格却在不断上涨，这种情况导致医药市场持续成长。

研究和开发受技术和科学进步的推动，特别是细胞和基因治疗，并在医药市场的成长中发挥关键作用。市场受到严格的监管和报销政策以及不断上升的研发成本的影响。人工智慧在製药业的多个领域得到应用并被认为至关重要，其中包括药物发现、临床试验、药物筛检、个人化医疗、药物安全检测和行销洞察。生成式 AI 工具可以透过自动执行繁琐且耗时的任务来帮助加速药物发现。

本研究评论包括 BCC Research 于 2023 年发布的有关抗肥胖药物、滥用药物检测、生物工程蛋白质药物以及疼痛管理药物和设备的报告的亮点和摘录，并提供了每个市场的全面概述、市场影响因素和市场机会的分析、法律制度、新兴技术和技术发展趋势、市场规模趋势和预测，以及各个细分市场和地区的详细分析。

目录

第 1 章 简介

2. 全球抗肥胖药物市场（PHM281A）

• 抗肥胖药物
• 市场概况
• 抗肥胖药物市场概况
• 成人肥胖和超重的定义
• 肥胖问题加剧
• 肥胖对全球经济的影响
• 提高对肥胖的认识
• 全球抗肥胖药物市场（按类型）
• 处方药
• 非处方药
• 全球抗肥胖药物市场（按分销管道）
• 医院药房
• 零售药局
• 网路药局
• 全球抗肥胖药物市场（按地区）
• 北美洲
• 欧洲
• 亚太地区
• 其他地区
• ESG 抗肥胖药物开发
• ESG 在减重药物产业的重要性
• 抗肥胖药物产业的 ESG 支柱
• ESG评级与指标：解读资料
• 减肥药产业的 ESG 实践
• BCC的结语

3. 药物滥用检测：技术与全球市场（PHM013J）

• 药物滥用检测的市场和技术背景
• 概述
• 检测技术
• 单参数和多参数测试
• DOA筛检
• 波特五力分析
• 药物滥用检测的市场动态
• 市场驱动因素
• 市场限制
• 市场机会
• 药物滥用检测的监管情景
• 北美洲
• 南美洲
• 中美洲和加勒比海地区
• 欧洲
• 亚太地区
• 全球药物滥用检测市场（按药物类型）
• 酒精
• 安非他命和甲基安非他命
• 大麻
• 古柯碱
• 阿片类药物
• 其他的
• 全球药物滥用检测市场（按最终用户划分）
• 药物检测实验室
• 医院
• 职场
• 其他的
• 全球药物滥用检测市场（按地区）
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

4. 全球生物工程蛋白质药物市场（BIO009H）

• 生物工程蛋白质药物
• 市场概况
• 生物工程蛋白质药物的市场及技术背景
• 蛋白质治疗概述
• 生物工程蛋白质药物
• 生物工程蛋白质药物製造技术
• 从天然来源（人类/动物）分馏/萃取
• 微生物发酵和生物反应器
• 基因改造
• 哺乳动物细胞培养
• 生物工程蛋白质药物的市场动态
• 市场推进因素
• 市场挑战
• 生物工程蛋白质药物市场按药物类型细分
• 概述
• 单株抗体（mAb）
• 肽激素
• 疫苗
• 融合蛋白
• 血液因素
• 胜肽类抗生素
• 细胞激素
• 治疗性酵素
• 生物工程蛋白质药物市场依疾病分类
• 概述
• 生物工程蛋白质药物市场按地区细分
• 北美市场按药物类型分類的收益
• 欧洲市场按药物类型分類的收益
• 新兴市场收益（按药物类型）
• 生物工程蛋白质药物市场的监管方面和新核准
• 新核准
• 市场新趋势/未来技术
• 双特异性和多特异性抗体
• 生物製药产业的主要趋势

5. 全球疼痛管理药物和设备市场（HLC026G）

• 疼痛管理药物和设备
• 市场概况
• 疼痛管理药物和设备市场亮点
• 疼痛管理药物和设备市场概况
• 疼痛史及疼痛治疗
• 疼痛感知
• 疼痛类型
• 疼痛评估
• 如何诊断疼痛
• 治疗疼痛的方法
• 疼痛管理药物和设备市场动态
• 市场驱动因素
• 市场限制
• 市场挑战
• 疼痛管理药物和设备市场按产品细分
• 药品
• 疼痛管理设备
• 疼痛管理药物和设备市场按应用细分
• 肌肉骨骼疼痛
• 术后疼痛
• 神经病变疼痛
• 癌症痛
• 偏头痛
• 其他的
• 疼痛管理药物和设备市场按地区细分
• 北美洲
• 欧洲
• 亚太地区
• 其他地区
• ESG 发展
• ESG：简介
• 疼痛管理药物和设备产业的永续性：ESG 视角
• 案例研究
• BCC的结语
• 疼痛管理药物和设备的新技术
• 概述
• 阿片类药物的技术进步
• 非麻醉药品的技术进步
• 神经调节设备的技术进步
• 输液帮浦的技术进步
• 疼痛管理趋势

第六章 附录

The global market for drugs of abuse (DOA) testing is estimated to increase from $5.2 billion in 2022 to reach $8.1 billion by 2027, at a compound annual growth rate (CAGR) of 9.3% from 2022 through 2027.

The global market for bioengineered protein drugs is estimated to increase from $354.1 billion in 2022 to reach $521.3 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.

The global market for pain management drugs and devices is expected to increase from $84.6 billion in 2023 to $109.9 billion by the end of 2028, with a compound annual growth rate (CAGR) of 5.4% during the forecast period of 2023-2028.

Research Review Scope

The pharmaceutical market is one of the biggest industries in the world, and it is continuously growing. Continuous and ongoing research and development are happening in the pharmaceutical market, with the entry of new drugs and the performance of the current drugs. However, a drug's entry into the market takes around 12-13 years, but the market for existing drugs keeps soaring, which is why the pharmaceutical market keeps growing.

Research and development play a vital role in the growth of the pharmaceutical market, driven by technological and scientific advancements, especially in cell and gene therapies. The market is affected by stringent regulatory and reimbursement policies and escalating research and development costs. Artificial intelligence can be considered crucial with its usage in multiple fields of pharmaceuticals, such as drug discovery, clinical trials, drug screening, personalized medicine, supply chain management, regulatory compliance, pharmacovigilance, and marketing insights. Generative AI tools help accelerate drug discovery by automating tedious and time-consuming tasks.

Research Reviews from BCC Research provide market professionals with concise market coverage within a specific research category. This 2023 Pharmaceuticals Research Review provides a sampling of the type of quantitative market information, analysis, and guidance that BCC Research has been developing since its inception in 1971 to help its customers make informed business decisions. This Research Review includes highlights and excerpts from the following reports published by BCC Research in 2023:

PHM281A Anti Obesity Drugs Market

• PHM013J Drugs of Abuse Testing: Technologies and Global Markets
• BIO009H Global Markets for Bioengineered Protein Drugs
• HLC026G The Global Market for Pain Management Drugs and Devices

After you survey the excerpts in this Research Review, we encourage you to follow up on these topics by checking out the full market research reports associated with each topic. BCC Research looks forward to serving your market intelligence needs in the future.

Table of Contents

Chapter 1 Foreword

• Research Review Scope

Chapter 2 Global Market for Anti-obesity Drugs (PHM281A)

• Anti-obesity Drugs
• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• Market Outlook
• Market Summary
• Market Overview of Anti-obesity Drugs
• Definitions of Adult Obesity and Overweight
• Rising Prevalence of Obesity
• Impact of Obesity on Global Economy
• Increasing Awareness Regarding Obesity
• Global Market for Anti-obesity Drugs, by Type
• Prescription Drugs
• Over-the-Counter Anti-obesity Drugs
• Global Market for Anti-obesity Drugs, by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Market for Anti-obesity Drugs, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World
• ESG Developments of Anti-obesity Drugs
• Importance of ESG in Anti-obesity Drugs Industry
• ESG Pillars in the Anti-obesity Drug Industry
• ESG Ratings and Metrics: Understanding the Data
• ESG Practices in the Anti-obesity Drug Industry
• Concluding Remarks from BCC

Chapter 3 Drugs of Abuse Testing: Technologies and Global Markets (PHM013J)

• Drugs of Abuse Testing
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Summary and Highlights
• Market and Technology Background of Drugs of Abuse Testing
• Overview
• Testing Technologies
• Single Tests vs. Multiparameter Tests
• DOA Screening
• Porter's Five Forces Analysis of Drugs of Abuse Testing
• Market Dynamics of Drugs of Abuse Testing
• Market Drivers
• Market Restraints
• Market Opportunities
• Regulatory Scenario of Drugs of Abuse Testing
• North America
• South America
• Central America and the Caribbean
• Europe
• Asia-Pacific
• Global Drugs of Abuse Testing Market, by Drug Type
• Alcohol
• Amphetamine and Methamphetamine
• Cannabis/Marijuana
• Cocaine
• Opioids
• Others
• Global Drugs of Abuse Testing Market, by End User
• Drug Testing Laboratories
• Hospitals
• Workplaces
• Others
• Market Breakdown of Drugs of Abuse Testing, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 4 Global Markets for Bioengineered Protein Drugs (BIO009H)

• Bioengineered Protein Drugs
• Study Goals and Objectives
• Scope of This Report
• Market Summary
• Market and Technology Background of Bioengineered Protein Drugs
• Protein Drugs Overview
• Bioengineered Protein Drugs
• Manufacturing Technologies of Bioengineered Protein Drugs
• Fractionation/Extraction from Natural Sources (Human/Animal)
• Microbial Fermentation and Bioreactors
• Transgenics
• Mammalian Cell Culture
• Market Dynamics of Bioengineered Protein Drugs
• Market Driver
• Market Challenges
• Market Breakdown of Bioengineered Protein Drugs by Drug Type
• Overview
• Monoclonal Antibodies (mAbs)
• Peptide Hormones
• Vaccines
• Fusion Proteins
• Blood Factors
• Peptide Antibiotics
• Cytokines
• Therapeutic Enzymes
• Market Breakdown of Bioengineered Protein Drugs, by Disease
• Overview
• Market Breakdown of Bioengineered Protein Drugs, by Region
• North America Market Revenue, by Drug Type
• Europe Market Revenue, by Drug Type
• Emerging Markets Revenue, by Drug Type
• Regulatory Aspects and New Approvals of Bioengineered Protein Drugs Market
• New Approvals
• Emerging Trends/Upcoming Technologies in the Market
• Bi- and Multi-Specific Antibodies
• Key Trends in Biopharmaceutical Industry

Chapter 5 Global Market for Pain Management Drugs and Devices (HLC026G)

• Pain Management Drugs and Device
• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• Market Outlook
• Market Summary
• Highlights of the Market for Pain Management Drugs and Devices
• Market Overview of Pain Management Drugs and Device
• History of Pain and Pain Treatment
• The Perception of Pain
• Types of Pain
• Assessment of Pain
• How Pain is Diagnosed
• How Pain is Treated
• Market Dynamics of Pain Management Drugs and Device
• Market Drivers
• Market Restraints
• Market Challenges
• Market Breakdown of Pain Management Drugs and Device, by Product
• Pharmaceuticals
• Pain Management Devices
• Market Breakdown of Pain Management Drugs and Device, by Application
• Musculoskeletal Pain
• Post-operative Pain
• Neuropathic Pain
• Cancer Pain
• Migraine/Headache
• Other Applications
• Market Breakdown of Pain Management Drugs and Device, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World
• ESG Development of Pain Management Drugs and Device
• Introduction to ESG
• Sustainability in the Pain Management Drugs and Devices Industry: An ESG Perspective
• Case Study
• Concluding Remarks from BCC
• Emerging Technologies of Pain Management Drugs and Device
• Overview
• Technology Advancements in Opioid Drugs
• Technology Advancements in Non-narcotic Drugs
• Technology Advancements in Neuromodulation Devices
• Technology Advancements in Infusion Pumps
• Trends in Pain Management

Chapter 6 Appendix

• Methodology
• Analyst's Credentials

List of Tables

• Table 1 : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
• Table 2 : Definitions of Adult Obesity and Overweight
• Table 3 : Number of People, Aged Over 5 Years, and Percentage of the Population With Overweight or Obesity, 2020-2035
• Table 4 : Global Obesity Trends for Children and Adolescents, Aged 5 to 19 Years, by Gender, 2020-2035
• Table 5 : Global Obesity Trends for Adults, Aged 20 Years and Above, by Gender, 2020-2035
• Table 6 : Global Economic Impact of High BMI (BMI >=25kg/m2), 2020-2035
• Table 7 : Global Market for Anti-obesity Drugs, by Drug Type, Through 2028
• Table 8 : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
• Table 9 : Global Market for Anti-obesity Drugs, by Region, Through 2028
• Table 10 : ESG Ratings and Metrics of Anti-obesity Drugs
• Table 11 : Environmental Performance of Anti-obesity Drugs
• Table 12 : Social Performance of Anti-obesity Drugs
• Table 13 : Governance Performance of Anti-obesity Drugs
• Table 14 : ESG Rankings for Major Anti-obesity Drug Companies, 2023*
• Table 15 : Global Market for Drugs of Abuse Testing, by Region, Through 2027
• Table 16 : Cutoff Concentrations for Initial and Confirmatory Drug Tests in Urine
• Table 17 : Deaths from Tobacco, Alcohol and Drugs, Across Countries, 2019
• Table 18 : Commonly Abused Drugs
• Table 19 : Prevalence of Drug Use in General, Population Across Region, 2020
• Table 20 : Global Drug Seizure, by Drug Type, 2020
• Table 21 : U.S. Drug Testing Legislation, by State, 2017
• Table 22 : European Drug Testing Legislation, by Country
• Table 23 : Global Market for Drugs of Abuse Testing, by Region, Through 2027
• Table 24 : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
• Table 25 : Characteristics of Large Molecule/Protein Drugs
• Table 26 : Bioengineered Protein Drugs vs. Chemically Synthesized Drugs
• Table 27 : Selected Protein Drugs Made, by Fractionation
• Table 28 : Selected Therapeutic Drugs Produced, by Microbial Fermentation
• Table 29 : Selected Protein Drugs Produced, by Transgenic Animals, Plants, and Microorganisms
• Table 30 : Selected Protein Drugs Made, by Cell Culture
• Table 31 : Number and Distribution of Persons Aged 60+, by Region, 2019 and 2050
• Table 32 : Global Pipeline Molecules, by Type, Through 2021
• Table 33 : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
• Table 34 : Percentage of Major Proteins Present in Different Fractions After Cohn's Fractionation Method
• Table 35 : Global Market for Bioengineered Protein Drugs, by Disease, Through 2027
• Table 36 : Global Market for Bioengineered Protein Drugs, by Region, Through 2027
• Table 37 : Newly Approved Monoclonal Antibodies (mAbs), January 2021-December 2022
• Table 38 : Newly Approved Peptide Hormones and Drugs, January 2021-December 2022
• Table 39 : Newly Approved Vaccines, January 2021-December 2022
• Table 40 : Vaccine Candidates in Clinical Phase, January 2021-December 2022
• Table 41 : Newly Approved Blood Factors, January 2021-December 2022
• Table 42 : Newly Approved Peptide Antibiotics, January 2021-December 2022
• Table 43 : Newly Approved Therapeutic Enzymes, January 2021-December 2022
• Table 44 : Newly Approved Cytokines, January 2021-December 2022
• Table 45 : Newly Approved Fusion Protein, January 2021-December 2022
• Table 46 : Selected Bi-Specific Antibodies in Phase 3 Clinical Trials, 2023
• Table 47 : Global Market for Pain Management Drugs and Devices, by Product, Through 2028
• Table 48 : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
• Table 49 : Objective Signs of Pain
• Table 50 : Prevalence of Chronic Pain in Older Adults, by Site
• Table 51 : Opioid Lawsuit Settlements
• Table 52 : Global Market for Pain Management Drugs and Devices, by Product, Through 2028
• Table 53 : FDA Pain Management Drug Approvals, 2020-2023
• Table 54 : Pain Management Major Drugs, by Company
• Table 55 : Emerging Pain Therapeutics
• Table 56 : Global Market for Pain Management Pharmaceuticals, by Product, Through 2028
• Table 57 : Global Market for Pain Management Devices, by Type, Through 2028
• Table 58 : Global Market for Pain Management Drugs and Devices, by Application, Through 2028
• Table 59 : Cumulative Volumes of Hip and Knee Procedures, 2012-2021
• Table 60 : Neuropathic Pain Medication
• Table 61 : Cancer Pain Medication
• Table 62 : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
• Table 63 : ESG Ranking of Major Pharma Players for Pain Therapeutics, 2022
• Table 64 : ESG Rankings for Major Pain Management Drug and Device Companies, 2023*
• Table 65 : ESG: Environmental Overview
• Table 66 : ESG: Social Overview
• Table 67 : ESG: Governance Overview

List of Figures

• Figure 1 : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
• Figure 2 : Global Market for Anti-obesity Drugs, by Drug Type, 2021-2028
• Figure 3 : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
• Figure 4 : Global Market Shares of Anti-obesity Drugs, by Region, 2021-2028
• Figure 5 : Global Market Shares of Drugs of Abuse Testing, by Region, 2021
• Figure 6 : Annual Self-reported Alcohol-impaired Driving Episodes Among U.S. Adults, 2010-2020
• Figure 7 : Legal Adult-Use Cannabis Sales Worldwide, 2020-2025*
• Figure 8 : Global Market Shares of Drugs of Abuse Testing, by Region, 2021
• Figure 9 : Global Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027
• Figure 10 : Global Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021
• Figure 11 : Global Market Shares of Bioengineered Protein Drugs, by Disease, 2021
• Figure 12 : Snapshot of Global Market for Bioengineered Protein Drugs, by Region
• Figure 13 : Global Market Shares of Bioengineered Protein Drugs, by Region, 2021
• Figure 14 : NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
• Figure 15 : Share of NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
• Figure 16 : Global Market for Pain Management Drugs and Devices, by Product, 2020-2028
• Figure 17 : Global Market for Pain Management Drugs and Devices, by Region, 2020-2028
• Figure 18 : Pain Management Techniques
• Figure 19 : Pain Management Drugs and Devices: Market Dynamics
• Figure 20 : Common Chronic Pain: Reasons
• Figure 21 : Cancer Incidence, by Region, 2020 vs. 2040
• Figure 22 : Percentage of Global Population Above 65 Years, 2018-2022
• Figure 23 : Global Market Shares of Pain Management Drugs and Devices , by Product, 2022
• Figure 24 : Global Market Shares of Pain Management Pharmaceuticals, by Product, 2022
• Figure 25 : Global Market Shares of Pain Management Devices, by Type, 2022
• Figure 26 : Global Market Shares of Pain Management Drugs and Devices, by Application, 2022
• Figure 27 : Classification of Neuropathic Pain
• Figure 28 : Causes of Cancer Pain
• Figure 29 : Burn Pain Management Approach
• Figure 30 : Global Market Shares of Pain Management Drugs and Devices, by Region, 2022
• Figure 31 : ESG Pillars
• Figure 32 : Advantages of ESG for Companies
• Figure 33 : ESG-Adoption Level across Industries
• Figure 34 : Hospitals: Sustainability Priorities
• Figure 35 : Novartis: ESG Rating
• Figure 36 : Novartis: Major ESG Activities, 2022